AVBP - NASDAQ
ArriVent BioPharma, Inc. Common Stock
$29.78
-0.47%ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
At a Glance
Live SnapshotArriVent BioPharma, Inc. Common Stock Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
ArriVent BioPharma, Inc. Common Stock Cash Flow Statement
AVBP • NASDAQ
| ArriVent BioPharma, Inc. Common Stock Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||
-166.3M | -80.5M | -69.3M | -36.9M | -51.6M | |
-3M | 0.0 | 0.0 | 0.0 | 0.0 | |
12.5M | 3.2M | 895K | 424K | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 43M | |
-3.8M | 7.1M | 12.6M | -7.1M | -3.9M | |
-160.6M | -70.2M | -55.8M | -43.6M | -12.6M | |
INVESTING ACTIVITIES | |||||
-272.9M | -194.2M | -25M | (0.0) | (0.0) | |
201.7M | 1.7M | 25M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | -40M | |
-71.2M | -192.5M | (0.0) | (0.0) | -40M | |
FINANCING ACTIVITIES | |||||
203.1M | 186M | 0.0 | 2K | 89.9M | |
-70K | 631K | -2.1M | 15K | 0.0 | |
203.1M | 186.6M | 42.9M | 169.7M | 89.9M | |
CASH FLOW SUMMARY | |||||
-28.8M | -76.1M | -13M | 126.1M | 37.3M | |
74.3M | 150.4M | 163.4M | 37.3M | 0.0 | |
45.5M | 74.3M | 150.4M | 163.4M | 37.3M | |
-160.6M | -70.2M | -55.8M | -43.6M | -12.6M |
SEC Filings
AVBP - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 18, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 17, 2026 | March 17, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 05, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 05, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 10, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 10, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 09, 2025 | September 09, 2025 | 2025 |
Related Guides
Continue your AVBP research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.